Cholic Acid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals Inc (NASDAQ: MIRM). Mirum will purchase Travere's bile acid product portfolio for up to $445 million, consisting of $210 million upfront and $235 million in potential sales-based milestone payments. Mirum will acquire Travere's rights to Cholbam, indicated for bile acid synthesis disorders due to

North America, Europe, China, Japan, Southeast Asia, India and ROW. Influence of the Cholic Acidmarket report: -Comprehensive assessment of all opportunities and risk in the Cholic Acid market. – Cholic Acid market recent innovations and major events. -Detailed study of business strategies for growth of the Cholic Acid market-leading players. -Conclusive study about the growth plot of Infrared Imaging market for forthcoming years. -In-depth understanding of Cholic Acidmarket-particular drivers, constraints and major micro markets. -Favourable impression inside vital technological and market...